Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein phosphatase 1 regulatory subunit 16A (PPP1R16A), also known as myosin phosphatase-targeting subunit 3 (MYPT3), is a regulatory protein that directs the activity of protein phosphatase 1 (PP1c) toward specific substrates such as myosin light chains. As part of the myosin light chain phosphatase complex (MLCP), PPP1R16A influences muscle contractility and intracellular motility by controlling the phosphorylation state of myosin light chains. Unlike other MYPT proteins, phosphorylation of PPP1R16A by protein kinase A leads to activation of PP1c, rather than inactivation. PPP1R16A is associated with certain diseases, most notably ovarian clear cell adenocarcinoma, and is involved in pathways like activation of cAMP-dependent PKA and beta-adrenergic signaling. No direct drug interactions or established clinical biomarkers are currently reported for this target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein phosphatase 1 regulatory subunit 16A (PPP1R16A).